3-hydroxybutyric acid has been researched along with Blood Poisoning in 12 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sepsis is a systemic inflammatory disease caused by multiple pathogens, with the most commonly affected organ being the lung." | 1.91 | 3-Hydroxybutyrate ameliorates sepsis-associated acute lung injury by promoting autophagy through the activation of GPR109α in macrophages. ( Dong, R; Gong, S; Huang, L; Huang, M; Jin, Y; Li, F; Li, X; Tang, X; Wang, X; Yang, H; Yu, Y; Zeng, Z, 2023) |
| "Sepsis is a major cause of acute kidney injury (AKI)." | 1.91 | β-hydroxybutyrate ameliorates sepsis-induced acute kidney injury. ( Kim, IY; Kim, MJ; Kim, SR; Kim, YS; Lee, DW; Lee, SB, 2023) |
| "Sepsis is a life-threatening condition of organ dysfunction caused by dysregulated inflammation which predisposes patients to developing cardiovascular disease." | 1.72 | Exogenous ketone ester administration attenuates systemic inflammation and reduces organ damage in a lipopolysaccharide model of sepsis. ( Dyck, JRB; Ferdaoussi, M; Maayah, ZH; Martens, MD; Silver, HL; Soni, S; Takahara, S; Ussher, JR, 2022) |
| "The 'obesity paradox' of critical illness refers to better survival with a higher body mass index." | 1.46 | Premorbid obesity, but not nutrition, prevents critical illness-induced muscle wasting and weakness. ( De Bock, K; Derde, S; Dufour, T; Goossens, C; Güiza, F; Hermans, G; Janssens, T; Langouche, L; Marques, MB; Thiessen, SE; Van den Berghe, G; Vander Perre, S; Vanhorebeek, I, 2017) |
| "Fatal ketoacidosis due to diabetes mellitus, alcoholism, and starvation may produce characteristic basal vacuolization of renal tubular epithelial cells (RTEC)." | 1.46 | Septic Ketoacidosis-A Potentially Lethal Entity with Renal Tubular Epithelial Vacuolization. ( Byard, RW; Zhou, C, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 7 (58.33) | 2.80 |
| Authors | Studies |
|---|---|
| Weckx, R | 1 |
| Goossens, C | 2 |
| Derde, S | 2 |
| Pauwels, L | 1 |
| Vander Perre, S | 2 |
| Van den Bergh, G | 1 |
| Langouche, L | 2 |
| Soni, S | 1 |
| Martens, MD | 1 |
| Takahara, S | 1 |
| Silver, HL | 1 |
| Maayah, ZH | 1 |
| Ussher, JR | 1 |
| Ferdaoussi, M | 1 |
| Dyck, JRB | 1 |
| Huang, M | 1 |
| Yu, Y | 1 |
| Tang, X | 1 |
| Dong, R | 1 |
| Li, X | 1 |
| Li, F | 1 |
| Jin, Y | 1 |
| Gong, S | 1 |
| Wang, X | 2 |
| Zeng, Z | 1 |
| Huang, L | 1 |
| Yang, H | 1 |
| Kim, MJ | 1 |
| Kim, YS | 1 |
| Kim, SR | 1 |
| Lee, DW | 1 |
| Lee, SB | 1 |
| Kim, IY | 1 |
| Song, Y | 1 |
| Chen, J | 1 |
| Zhang, S | 1 |
| Le, Y | 1 |
| Xie, Z | 1 |
| Ouyang, W | 1 |
| Tong, J | 1 |
| Soto-Mota, A | 1 |
| Norwitz, NG | 1 |
| Clarke, K | 1 |
| Ginn, C | 1 |
| Ateh, D | 1 |
| Martin, J | 1 |
| Marques, MB | 1 |
| Dufour, T | 1 |
| Thiessen, SE | 1 |
| Güiza, F | 1 |
| Janssens, T | 1 |
| Hermans, G | 1 |
| Vanhorebeek, I | 1 |
| De Bock, K | 1 |
| Van den Berghe, G | 1 |
| Zhou, C | 1 |
| Byard, RW | 1 |
| Tanaka, J | 1 |
| Kono, Y | 1 |
| Shimahara, Y | 1 |
| Sato, T | 1 |
| Jones, RT | 1 |
| Cowley, RA | 1 |
| Trump, BF | 1 |
| Beylot, M | 1 |
| Chassard, D | 1 |
| Chambrier, C | 1 |
| Guiraud, M | 1 |
| Odeon, M | 1 |
| Beaufrère, B | 1 |
| Bouletreau, P | 1 |
| Yassen, KA | 1 |
| Galley, HF | 1 |
| Lee, A | 1 |
| Webster, NR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Safety and Tolerability of Exogenous Ketosis Induced by Free Beta-hydroxybutyrate.[NCT05584371] | 30 participants (Anticipated) | Interventional | 2022-10-31 | Recruiting | |||
| Comparison Between Endogenous and Exogenous Ketosis in Patients With Non-ischemic Chronic Heart Failure With Reduced Ejection Fraction[NCT04921293] | 18 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 3-hydroxybutyric acid and Blood Poisoning
| Article | Year |
|---|---|
Why a d-β-hydroxybutyrate monoester?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus; Diet, Ketogenic; Dietary Supplements; Epilepsy; Fasting; H | 2020 |
Why a d-β-hydroxybutyrate monoester?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus; Diet, Ketogenic; Dietary Supplements; Epilepsy; Fasting; H | 2020 |
Why a d-β-hydroxybutyrate monoester?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus; Diet, Ketogenic; Dietary Supplements; Epilepsy; Fasting; H | 2020 |
Why a d-β-hydroxybutyrate monoester?
Topics: 3-Hydroxybutyric Acid; Diabetes Mellitus; Diet, Ketogenic; Dietary Supplements; Epilepsy; Fasting; H | 2020 |
The use of point-of-care testing to establish cause of death in the autopsy setting.
Topics: 3-Hydroxybutyric Acid; Autopsy; Bacteria; Blood Alcohol Content; Blood Glucose; C-Reactive Protein; | 2020 |
1 trial available for 3-hydroxybutyric acid and Blood Poisoning
| Article | Year |
|---|---|
Metabolic effects of a D-beta-hydroxybutyrate infusion in septic patients: inhibition of lipolysis and glucose production but not leucine oxidation.
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Analysis of Variance; Carbon Isotopes; Depression, C | 1994 |
9 other studies available for 3-hydroxybutyric acid and Blood Poisoning
| Article | Year |
|---|---|
Identification of the toxic threshold of 3-hydroxybutyrate-sodium supplementation in septic mice.
Topics: 3-Hydroxybutyric Acid; Acid-Base Equilibrium; Aldosterone; Animals; Brain; Dietary Supplements; Dose | 2021 |
Exogenous ketone ester administration attenuates systemic inflammation and reduces organ damage in a lipopolysaccharide model of sepsis.
Topics: 3-Hydroxybutyric Acid; Animals; Anti-Inflammatory Agents; Cardiovascular Diseases; Esters; Inflammat | 2022 |
3-Hydroxybutyrate ameliorates sepsis-associated acute lung injury by promoting autophagy through the activation of GPR109α in macrophages.
Topics: 3-Hydroxybutyric Acid; Acute Lung Injury; Animals; Autophagy; Lung; Macrophages; Mice; Sepsis; Ultra | 2023 |
β-hydroxybutyrate ameliorates sepsis-induced acute kidney injury.
Topics: 3-Hydroxybutyric Acid; Acute Kidney Injury; Animals; Apoptosis; Kidney; Lipopolysaccharides; Male; M | 2023 |
Subcutaneous administration of β-hydroxybutyrate improves learning and memory of sepsis surviving mice.
Topics: 3-Hydroxybutyric Acid; Animals; Cognitive Dysfunction; Hippocampus; Injections, Intraventricular; In | 2020 |
Premorbid obesity, but not nutrition, prevents critical illness-induced muscle wasting and weakness.
Topics: 3-Hydroxybutyric Acid; Aged; Animals; Body Composition; Critical Illness; Fasting; Fatty Acids; Fema | 2017 |
Septic Ketoacidosis-A Potentially Lethal Entity with Renal Tubular Epithelial Vacuolization.
Topics: 3-Hydroxybutyric Acid; Adult; Aged; Epithelial Cells; Fatal Outcome; Female; Humans; Ketones; Ketosi | 2017 |
A study of oxidative phosphorylative activity and calcium-induced respiration of rat liver mitochondria following living Escherichia coli injection.
Topics: 3-Hydroxybutyric Acid; Adenosine Diphosphate; Animals; Calcium; Escherichia coli Infections; Glutama | 1982 |
Mitochondrial redox state in the critically ill.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Biomarkers; Critical Illness; Humans; Ketone Bodi | 1999 |